Dr. Nahal R. Lalefar

Claim this profile

UCSF Benioff Children's Hospital Oakland

Studies Acute Lymphoblastic Leukemia
Studies Burkitt Lymphoma
4 reported clinical trials
12 drugs studied

Area of expertise

1

Acute Lymphoblastic Leukemia

Nahal R. Lalefar has run 2 trials for Acute Lymphoblastic Leukemia. Some of their research focus areas include:

NGS-MRD negative
Stage II
Stage I
2

Burkitt Lymphoma

Nahal R. Lalefar has run 1 trial for Burkitt Lymphoma. Some of their research focus areas include:

NGS-MRD negative

Affiliated Hospitals

Image of trial facility.

UCSF Benioff Children's Hospital Oakland

Image of trial facility.

Children's Hospital & Research Center - Oakland

Clinical Trials Nahal R. Lalefar is currently running

Image of trial facility.

Non-TBI Conditioning

for HCT in Acute Lymphoblastic Leukemia

This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT). Patients diagnosed with B-ALL who are candidates for HCT will be screened by NGS-MRD on a test of bone marrow done before the HCT. Subjects who are pre-HCT NGS-MRD negative will be eligible to receive a non-TBI conditioning regimen as part of the treatment cohort of the study. Subjects who are pre-HCT NGS-MRD positive will be treated as per treating center standard and will be followed in an observational cohort (HCT center standard of care).

Recruiting

1 award

Phase 2

Image of trial facility.

Letermovir

for Preventing Infection After Stem Cell Transplant in Blood Cancer

This phase III single arm trial determines whether taking prophylactic letermovir will reduce the likelihood of infection with cytomegalovirus (CMV) in children and adolescents after stem cell transplant compared to estimated rate of infection without prophylaxis. The treatments used to prepare for HCT reduce the body's natural infection-fighting ability and increase the likelihood of an infection with a virus called cytomegalovirus. "Prophylaxis" means to take a drug to prevent a disease or side effect. Letermovir is an antiviral drug that stops cytomegalovirus from multiplying and may prevent cytomegalovirus infection and make the disease less severe.

Recruiting

2 awards

Phase 3

5 criteria

More about Nahal R. Lalefar

Clinical Trial Related

7 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Nahal R. Lalefar has experience with

  • Myeloablative Allogeneic HCT With A Non-TBI Conditioning Regimen
  • NGS-MRD
  • Haploidentical Hematopoietic Cell Transplantation (haploHCT)
  • Matched Unrelated Donor Hematopoietic Cell Transplantation (MUD-HCT)
  • Letermovir
  • Cyclophosphamide

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Nahal R. Lalefar specialize in?

Is Nahal R. Lalefar currently recruiting for clinical trials?

Are there any treatments that Nahal R. Lalefar has studied deeply?

What is the best way to schedule an appointment with Nahal R. Lalefar?

What is the office address of Nahal R. Lalefar?

Is there any support for travel costs?